The primary objective of this study is to determine the percentage of patients with a plasma concentration of sunitinib remaining at equilibrium (\[Suni\]REq) greater than 100 ng / ml (effective concentration according to the current literature).
The secondary objectives of this study are: * To describe the distribution of constitutional genetic determinants related to sunitinib pharmacokinetics, and to study their correlation with * the \[Suni\]REq, * the advent of toxicity, * the tumor response. * To describe the variation in the \[Suni\]REq and the plasma concentration of the active entity remaining at equilibrium (\[ActEnt\]REq) at: * the interindividual level, * overtime, between chemotherapy cycles. * To describe the variation in the ratio of the plasma concentration of the metabolite remaining at equilibrium (\[Metab\]REq) to the \[Suni\]REq at: * the interindividual level, * overtime, between chemotherapy cycles. * To explore potential correlations between the \[Suni\]REq and * toxicity, * tumor response. * To explore potential correlations between the \[ActEnt\]REq and * toxicity, * tumor response. * To explore potential correlations between the ratio \[Metab\]REq / \[Suni\]REq and * toxicity, * tumor response.
Study Type
OBSERVATIONAL
Enrollment
43
Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.\* \*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
CHRU de Montpellier - Hôpital Saint-Eloi
Montpellier, France
CHRU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, France
Institut de Cancérologie du Gard (ICG)
Nîmes, France
The percentage of patients with a plasma concentration of sunitinib remaining at equilibrium ([Suni]REq) greater than 100 ng / ml
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between C1D15* and C1D28*
Genotype: genetic polymorphisms of enzymes of phase I, phase II (conjugation), carriers of Phases 0 and III, the nuclear receptors PXR and CAR, pharmacological targets of sunitinib (tyrosine kinase receptors).
Predefined list of genes: ABCB1 ABCC2 ABCG2 CYP1A1 CYP1A2 CYP2A6 CYP2B6 CYP2C19 CYP2C8 CYP2C9 CYP2D6 CYP2E1 CYP3A4 CYP3A5 NR1I2 NR1I3 SLC15A2 SLC22A1 SLC22A2 SLC22A6 SLCO1B1 SLCO1B3 SULT1A1 UGT1A1 UGT2B15 UGT2B17 UGT2B7 VEGFR1,2,3 PDGFR-α et β KIT
Time frame: Baseline (day 0)
[Suni]REq per cure
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between CmD15* and CmD28* for 18 months
The presence/absence of grade I, II, III, IV, V (CTCAE version 4.0) toxicities per cure
Time frame: 18 months
Tumor response per cure
Time frame: 18 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Toxicity (yes/no) for each type of toxic event per cure
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between CmD15* and CmD28* for 18 months
[Suni]REq at the 1st cure, averaged per initial dosing (37.5mg, 50 mg, 75 mg, 100mg)
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between C1D15* and C1D28*
the average [Suni]REq over all cures
Time frame: 18 months
For each cure, the average [Suni]REq for cure 1 to cure m
Time frame: 18 months
For each cure, the ratio of the plasma concentration of the metabolite remaining at equilibrium ([Metab]REq) / [Suni]REq
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between CmD15* and CmD28* for 18 months
[Metab]REq / [Suni]REq
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between C1D15* and C1D28*
[Metab]REq / [Suni]REq averaged per initial dosing
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between C1D15* and C1D28*
Mean [Metab]REq / [Suni]REq for all cures
Time frame: 18 months
For each cure, the average [Metab]REq / [Suni]REq for cure 1 to cure m
Time frame: 18 months
For each cure, the plasma concentration of the active entity remaining at equilibrium ([ActEnt]REq)
Time frame: 18 months
[ActEnt]REq
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between C1D15* and C1D28*
[ActEnt]REq averaged per initial dosing
\*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle.
Time frame: Between C1D15* and C1D28*
Mean [ActEnt]REq for all cures
Time frame: 18 months
For each cure, the average [ActEnt]REq for cure 1 to cure m
Time frame: 18 months
For each cure, the % of patients whose dosings were modified since the beginning of the study
Time frame: 18 months
Presence/absence of side effects noted in the summary of product characteristics for sunitinib
Time frame: 18 months